GlassScriptPhysician profile
Bahador Momeni
NPI 1164428264
$1,214.05
in general payments reported to CMS, 2019-2025
17 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.33 · 2020: $24.01 · 2022: $67.81 · 2023: $356 · 2024: $446 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266.88 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $236.78 | 2022-2025 | |
| Glaxosmithkline, LLC. | $170.70 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $162.81 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $49.04 | 2024-2025 | Korlym |
| Abbvie INC. | $41.00 | 2023-2024 | |
| Bsn Medical INC | $39.92 | 2024 | |
| Amgen INC. | $38.42 | 2023-2025 | Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $33.13 | 2024 | |
| Astellas Pharma US INC | $25.21 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $24.06 | 2022 | |
| Medline Industries LP | $24.01 | 2020 | |
| Neos Therapeutics, LP | $23.81 | 2023 | Adzenys Xr-Odt |
| Exact Sciences Corporation | $21.21 | 2024 | Cologuard Collection Kit |
| Taiho Oncology, INC. | $20.88 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $19.23 | 2023 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $16.96 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahador Momeni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.